Izzy Manhal, Angirekula Mounika, Abu Dayyeh Barham K, Bazerbachi Fateh, Watt Kymberly D
Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA.
Gastroenterol Rep (Oxf). 2020 Nov 24;9(3):252-256. doi: 10.1093/gastro/goaa057. eCollection 2021 Jun.
Obesity is commonly observed in patients with cirrhosis, especially with the increasing prevalence of non-alcoholic steatohepatitis (NASH). Bariatric surgery has been avoided in these patients given concerns about increased perioperative risk; therefore, data are lacking regarding long-term outcomes. In this study, we aimed to evaluate the long-term outcomes of patients with cirrhosis who underwent bariatric surgery.
We reviewed the charts of adult patients with compensated cirrhosis who underwent bariatric surgery after they were prospectively enrolled between February 23, 2009 and November 9, 2011, and followed in a pilot study for evaluation of bariatric surgery outcomes. Only patients with more than 4 years of follow-up were included in the analysis. Data regarding their liver disease, metabolic status, and survival were collected. A descriptive analysis was performed.
The cohort consisted of 10 patients, of whom 7 were females. The median post-surgical follow-up was 8.7 years (± 1.4 years). All patients had biopsy-proven NASH; two patients had concurrent, untreated hepatitis C infection. During the observation period, there was a mean weight loss of 24 kg (19.2% of total body weight pre surgery, <0.001) and only one patient regained weight to the baseline pre-surgical measurement. One patient who was not eligible for transplant developed hepatic encephalopathy 3 years after surgery and later died. The remainder of the patients did not have any hepatic decompensation, cardiovascular event, or mortality. Except for one patient with Gilbert syndrome, bilirubin was normal in all patients at last follow-up.
Bariatric surgery in patients with compensated cirrhosis can lead to sustained weight loss and stable hepatic function on long-term follow-up.
肥胖在肝硬化患者中很常见,尤其是随着非酒精性脂肪性肝炎(NASH)患病率的增加。鉴于对围手术期风险增加的担忧,这些患者一直避免接受减肥手术;因此,缺乏关于长期预后的数据。在本研究中,我们旨在评估接受减肥手术的肝硬化患者的长期预后。
我们回顾了2009年2月23日至2011年11月9日期间前瞻性入组并在一项减肥手术结局评估的试点研究中进行随访的成年代偿期肝硬化患者的病历。仅纳入随访超过4年的患者进行分析。收集有关他们肝脏疾病、代谢状况和生存的数据。进行描述性分析。
该队列由10名患者组成,其中7名女性。术后中位随访时间为8.7年(±1.4年)。所有患者均经活检证实患有NASH;两名患者同时感染了未经治疗的丙型肝炎。在观察期内,平均体重减轻了24千克(占术前总体重的19.2%,<0.001),只有一名患者体重恢复到术前基线测量值。一名不符合移植条件的患者在术后3年发生肝性脑病,随后死亡。其余患者没有任何肝失代偿、心血管事件或死亡。除一名患有吉尔伯特综合征的患者外,所有患者在最后一次随访时胆红素均正常。
代偿期肝硬化患者接受减肥手术可导致长期随访中体重持续减轻和肝功能稳定。